VeraDermics Inc (MANE)
NYSEHealth CareBiotechnologySnapshot 2026-07-09
$119.60-4.25%
Close 2026-07-10 · 1-day change
Reading MANE? Create a free portfolio, then add this holding for ongoing Reports and tracking. No credit card.
Create your account →NYSEHealth CareBiotechnologySnapshot 2026-07-09
Reading MANE? Create a free portfolio, then add this holding for ongoing Reports and tracking. No credit card.
Create your account →QuarterlyIQ Insights · MANE
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Unregistered Sales of Equity Securities. The information contained in
Entry into a Material Definitive Agreement. On May 1, 2026, Veradermics, Incorporated (the “Company”) closed its underwritten public offering (the “Public Offering”) of 3,843,790 shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), at a public offering price of $100.00 per share, pursuant to the Company’s registration statements on Form S-1 (File Nos. 333-295356 and 333-295420). In addition, the Company has granted the underwriters an option for a period of…
Results of Operations and Financial Condition. Veradermics, Incorporated (the “Company”) reports that it had a preliminary unaudited amount of cash, cash equivalents and marketable securities of approximately $390.8 million as of March 31, 2026. This amount is preliminary and unaudited and is subject to completion of the Company’s financial closing procedures. As a result, this amount may differ materially from the amount that will be reflected in the Company’s unaudited condensed consolidate…
of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.